Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Wheat, JC; Weizer, AZ; Wolf, JS; Lotan, Y; Remzi, M; Margulis, V; Wood, CG; Montorsi, F; Roscigno, M; Kikuchi, E; Zigeuner, R; Langner, C; Bolenz, C; Koppie, TM; Raman, JD; Fernndez, M; Karakiewizc, P; Capitanio, U; Bensalah, K; Patard, JJ; Shariat, SF.
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy.
Urol Oncol. 2010; 30(3):252-258 Doi: 10.1016/j.urolonc.2010.01.001
Web of Science PubMed FullText FullText_MUG Google Scholar

Co-authors Med Uni Graz: Langner Cord; Zigeuner Richard
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Objective: Carcinoma in situ (OS) is associated with increased risk of progression when found with high-grade non-muscle-invasive bladder cancer, yet its impact is less clear in the upper urinary tract. In the current study, we evaluated the impact of concomitant CIS on recurrence-free survival and cancer-specific survival following radical nephroureterectomy for upper tract urothelial carcinoma (UTUC). Materials and methods: A multi-institutional retrospective cohort of 1,387 patients undergoing radical nephroureterectomy was identified. Concomitant CIS was defined as the presence of CIS in association with another pathologic stage; patients with CIS alone were excluded from the analysis. The presence of concomitant CIS served as the exposure variable with disease recurrence and cancer-specific mortality as the outcomes. Organ-confined disease was defined as AJCC/UICC stage II or lower. Results: Concomitant CIS was identified in 371 of 1,387 (26.7%) patients and was significantly more common in patients with a previous bladder cancer history, high grade, and high stage tumors. In a multivariable analysis, concomitant CIS was a predictor of disease recurrence (HR = 1.25, P = 0.04) and cancer specific mortality (HR = 1.34, P = 0.05) for patients with organ-confined UTUC, but not in the entire cohort. Other prognostic variables, such as grade, stage, lymphovascular invasion, and lymph node status, were associated with poorer overall and recurrence-free survival for all patients. Conclusion: The presence of concomitant CIS in patients with organ-confined UTUC is associated with a higher risk of recurrent disease and cancer-specific mortality. This information may be useful in refining surveillance protocols and in more appropriate selection of patients for adjuvant chemotherapy. (C) 2012 Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Aged, 80 and over -; Carcinoma - diagnosis; Carcinoma in Situ - diagnosis; Cohort Studies -; Disease Progression -; Female -; Humans -; Male -; Middle Aged -; Models, Statistical -; Nephrectomy - methods; Palpation - methods; Prognosis -; Recurrence -; Retrospective Studies -; Risk -; Ureter - surgery; Urinary Bladder Neoplasms - diagnosis; Urinary Tract - surgery; Urothelium - surgery
Find related publications in this database (Keywords): Transitional cell carcinoma; Nephroureterectomy; Carcinoma in situ; Upper tract